Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
NCT ID NCT04294498
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if durvalumab causes the virus to reactivate or leads to liver inflammation. The trial enrolls 30 adults with confirmed liver cancer and active hepatitis B.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug) given alongside entecavir (an antiviral drug)
What this could lead to
If successful, this could expand treatment options for liver cancer patients who also have active hepatitis B, without requiring strict viral suppression beforehand.
What could go wrong
This is a small, early-phase study (30 participants) focused on safety, not yet proving the drug works against the cancer. There is still a risk of hepatitis B flare-ups or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
Taipei, 10002, Taiwan